WO2002078761A1 - Neo-tissu cartilagineux greffable - Google Patents
Neo-tissu cartilagineux greffable Download PDFInfo
- Publication number
- WO2002078761A1 WO2002078761A1 PCT/FR2002/001122 FR0201122W WO02078761A1 WO 2002078761 A1 WO2002078761 A1 WO 2002078761A1 FR 0201122 W FR0201122 W FR 0201122W WO 02078761 A1 WO02078761 A1 WO 02078761A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- chitosan
- hydrogel
- tissue
- neo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3654—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
- A61L27/3856—Intervertebral discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/72—Chitin, chitosan
Definitions
- the present invention relates to the field of repairing cartilage lesions by the implementation of a graft. It relates more particularly to a graftable cartilage tissue.
- Cartilage is a tissue of mesenchymal origin consisting of a small percentage of chondrocytes distributed within an extracellular matrix which they ensure renewal.
- This matrix is composed of a network of collagen fibers, in particular type II, and of glycosaminoglycans associated with structural proteins to form proteoglycans. The whole by its amphiphilic nature and its ionic sites forms a physical gel ensuring the viscoelastic properties of the cartilaginous tissue.
- cartilage tissue disappears in adulthood except at the level of the joints, where its role is to ensure the movement of the articular surfaces and to support significant compressive loads. Joint cartilage is however not able to regenerate spontaneously. This is why in case of cartilage lesions recourse is had to transplant techniques, such as mosaic grafting or grafting of autologous cells.
- Mosaic grafting involves taking samples of bone covered with cartilage in non-bearing regions and grafting them at the level of the lesion.
- Autologous cell transplantation consists of taking a sample of healthy cartilage, subjecting it to an enzymatic digestion in order to free the chondrocytes from the extra cellular matrix, making the chondrocytes multiply ex-vivo until a sufficient number is obtained. chondrocytes, which are then reimplanted in the cartilage lesion. Chondrocytes in the form of a cell suspension in aqueous medium (dispersion in a liquid medium), first cover the previously unbridled lesion with a membrane made of periosteum sutured tightly at the edge of the cartilage and then inject the suspension (dispersion containing the culture) into the cavity thus created chondrocytes. After a certain time, these cells produce an extra-cellular matrix which does not however have the tissue organization of normal articular cartilage.
- the mode of multiplication of the chondrocytes to be implanted must be determined so as to avoid a dedifferentiation of the cells.
- chondrocytes are made to proliferate on a support (synthetic polymer) like that of the bottom of the cell culture dishes, the chondrocytes become differentiated into fibroblastic cells. They are then spindle-shaped instead of being polygonal like chondrocytes and synthesize collagen I instead of collagen II.
- the polysaccharides are chosen in particular from the following compounds: dextran, cellulose, arabinogalactan, pollulan and amylose.
- the crosslinking agent is for example glutamic acid, lysine, albumin or gelatin.
- the chondrocytes multiply while keeping their shape and their phenotype, and synthesize very particularly collagen II.
- the chondrocytes are recovered by digesting the polysaccharide beads using specific enzymes, for example dextranase, which do not damage the chondrocytic cells. Said cells are then detached to be included in a chitosan matrix. To do this, chondrocytes are added to an acidic solution of chitosan, then the mixture is stirred until the formation of a three-dimensional structure which is placed in a 1N sodium hydroxide solution so as to obtain the precipitation of the chitosan. in a few minutes. After polymerization, the sodium hydroxide is quickly eliminated and the polymerized conglomerate of chitosan and cells is cultured at 37 ° C., 5% CO 2 for a determined period.
- specific enzymes for example dextranase
- the chondrocytes mixed with the chitosan are incorporated into the three-dimensional structure of the precipitated chitosan, which structure would have a firm consistency resembling the texture of the cartilage.
- Chitosan is obtained by deacetylation of chitin, the most widespread biopolymer in nature after cellulose. Chitin can be extracted from the exoskeleton of certain crustaceans such as lobster, crab or the squid endoskeleton, for example. Chitin and chitosan consist of the same two monomer units, N-acetylD glucosamine and D-glucosamine. When the polymer is strongly acetylated, that is to say when it comprises more than 60% of N-acetyl-D-glucosamine, it is called chitin. Both are biodegradable, bioresorbable and compatible with living tissue. Chitosan is known to have a biostimulating activity on the reconstitution of tissues.
- chitosan is combined with another polysaccharide to form an agent for stimulating the regeneration of hard tissue at an integration site of an implant, for example made of titanium.
- the chitosan is crosslinked with a glycosaminoglycan to constitute a biochemical environment close to the cartilaginous tissue, stimulating cell growth.
- the methods which are described in documents WO.OO / 56251 and WO.99 / 47186 are based on the so-called scaffold technique, according to which the cells are incorporated, included, in a three-dimensional structure which forms a scaffolding, a framework.
- This three-dimensional structure constituted in particular by chitosan alone in document WO.OO / 56251 or associated with other constituents in document WO.99 / 47186, forms an integral part of the material intended to be grafted.
- the graftable cartilage tissue of the present invention differs from the teaching of the preceding documents in that it does not comprise any component forming a three-dimensional structure of the scaffold type.
- this graftable cartilaginous neo-tissue consists of more or less parallel rows of cells, having a gradient of cell maturation oriented from a determined zone towards its periphery.
- Such a graftable cartilage tissue is in particular obtained by a process which consists of: a) culturing chondrogenic cells, which are either autologous chondrocytes or precursor cells of chondrocytes prepared in vitro from pluripotent stem cells, b) bringing said chondrogenic cells into contact with a chitosan hydrogel whose properties the amphiphilia and the degree of acetylation are such that the said cells adhere naturally to the external surface of the said hydrogel, c) covering the whole hydrogel / cells thus obtained with a culture medium and, d) allowing a neo- cartilage tissue in contact with chitosan hydrogel for a minimum of two weeks, frequently renewing the culture medium.
- the natural adhesion of the cells to the external surface of the chitosan hydrogel makes it possible to obtain a very good distribution of said cells and avoids the loss of cells during the operation, for example when this is carried out in wells. culture.
- the chitosan hydrogel plays a role in inducing the phenotype of chondrogenic cells, which proliferate without being indifferentiated.
- the chondrogenic cells do not penetrate directly inside the hydrogel, the latter having insufficient porosity with regard to the size of said cells.
- the hydrogel of chitosan is gradually metabolized and / or replaced and / or invaded by matrix proteins of the cartilage type, which are neosynthesized by chondrocytes. After at least two weeks of culture, the whole produces a cartilaginous neo-tissue which can be grafted as it is, the chitosan hydrogel which temporarily serves as a support for this cartilaginous neo-tissue being partly or entirely biodegraded.
- the degree of acetylation of chitosan, used for the preparation of the hydrogel is between 30 and 70%; preferably this is between 40 and 60%.
- the chondrogenic cells are brought into contact with the chitosan hydrogel which is in the form of small particles of a few millimeters.
- the chondrogenic cells are spread in the form of at least one layer on a layer or between at least two layers of chitosan hydrogel, each layer being of the order of a few millimeters thick. This particular arrangement makes it very easy to obtain a large cartilage neo-tissue, after complete disappearance of the chitosan hydrogel.
- the neo-cartilage tissue formed in particular by the process of the invention is characterized in that it is made up of more or less parallel rows of cells, having a cell maturation gradient oriented from a determined zone towards its periphery, the zone determined corresponding to the junction area of the cells with the chitosan hydrogel.
- this neo-tissue is analyzed in histology, its morphological appearance is close to a normal cartilage tissue.
- the present invention will be better understood on reading the description which will be made of several examples of the preparation of a cartilage neo-tissue using as an amplification support a chitosan hydrogel whose degree of acetylation is between 40 and 60%.
- the reference chitosan used is obtained from endoskeletons of squid. It has an acetylation degree of 5.2%. It is first of all purified in order to remove the insoluble particles, by implementing the following stages: dissolution, filtration, precipitation, washing and lyophilization.
- a solution of low viscosity is prepared, with a concentration of the order of 0.5% by weight of chitosan in an acid solution. More specifically, acetic acid is put in a stoichiometric amount relative to the amino groups of chitosan.
- the polymer solution is filtered by successive passages on membranes of decreasing porosity (1.2; 0.8 and 0.45 ⁇ m) under a maximum pressure of 3 bars.
- the polymer is precipitated by raising the pH of the solution by adding a concentrated ammonia solution, with stirring.
- the suspension is centrifuged and the pellet recovered. Washing takes place until the pH of the washing water stabilizes at a value which is a function of the degree of acetylation.
- Lyophilization makes it possible to obtain the chitosan in solid form.
- the chitosan is then re-acetylated to obtain the degree desired acetylation.
- This reacetylation is carried out by reaction of the amino function with acetic anhydride in a hydro-alcoholic medium. The ratio between the number of amino functions and the number of anhydride molecules present in solution determines the degree of acetylation of the chitosan produced.
- a hydroalcoholic solution which comprises, in addition to chitosan, water, 1,2-propanadiol and the necessary quantity of acetic acid to have a quantity stoichiometric with respect to the amino functions of chitosan.
- the hydro-alcoholic solution included 3 g of chitosan, 323 g of water and 272 g of 1,2-propanadiol.
- the acetylating mixture comprises acetic anhydride and propanediol.
- the mixture included 1.26 ml of acetic anhydride to obtain a degree of acetylation of chitosan of 50% and 1.62 ml of acetic anhydride to obtain a degree of acetylation of 60% .
- the preferred preparation method starts with an initial solution of chitosan. If necessary, depending on the degree of acetylation, it will be an acid solution, the c hitosane being dissolved in hydrochloric acid in stoichiometric amount with the amino groups of chitosan. After complete dissolution of the chitosan, a certain volume of 1.2 propanediol is added dropwise to the solution which is then degassed under vacuum for a period of approximately one hour.
- the solution is then poured into a container making it possible to have a large free surface to volume ratio and is placed in an oven at 45 ° C. for the time necessary for it to gel.
- the formation of the chitosan hydrogel is obtained by a physicochemical process.
- hydrogel which is not soluble in water at pHs of the order of 6 or 7
- neutralization of the hydrogel thus obtained is carried out for approximately one hour in basic medium, for example sodium hydroxide. 0.1 molar.
- the decrease in the number of positive charges due to the increase in pH promotes hydrophobic interactions and therefore the stability of the gel.
- the hydrogel is then washed to remove the alcohol and obtain a pH of approximately 7. It is this chitosan hydrogel, washed, which will be used for the cultivation of the chondrogenic cells.
- the gel corresponds to a determined aqueous solution / 1-2 propanediol ratio, a ratio which depends on the degree of acetylation of the chitosan.
- the gelation being accompanied by a loss of water, it is important that the operating conditions favor this evaporation of the water.
- containers can be used during gelation, whether they are petri dishes, multi-well dishes or inserts specially designed to be housed in the wells of multi-well dishes.
- a 24-well plate equipped with inserts is used, each insert consisting of a plastic cone, the bottom of which is formed from a membrane permeable to nutrition liquid and which is arranged to be deposited in each well. without touching the bottom.
- Chondrogenic cells can be chondrocytes autologous or precursor cells of chondrocytes prepared, in vitro, from pluripotent stem cells.
- the hydrogel obtained is in the form of a visco-elastic and translucent block, the capacity and resistance of which depend in particular on the concentration of chitosan in the initial solution. .
- this concentration is 0.5 to 4%.
- the block of chitosan hydrogel is cut into small fragments whose external dimensions are of the order of a few millimeters. These fragments are placed in the wells of a multi-well plate or possibly in the inserts equipping such a plate.
- the chondrogenic cells are introduced in the form of a suspension and mixed delicately with the hydrogel fragments. The whole is covered with an appropriate culture medium. It is found that the chondrogenic cells spontaneously adhere to the outer surface of the hydrogel fragments and do not fall into the bottom of the wells.
- the cultivation is carried out by placing the plates thus garnished in an atmosphere of 10% CO 2 at 37 ° C.
- the nutrition medium is renewed twice a week.
- the cultivation continues for a variable time which can range from 2 to 6 weeks depending on the size desired for the cartilage neo-tissue which forms on contact with the chitosan hydrogel.
- the degree of acetylation between 30 and 70%, but preferably between 40 and 60% induces optimal amphiphilic conditions favorable to the establishment of an environment conducive to the synthesis of the cartilage neo-tissue. Indeed, by increasing the degree of acetylation, one contributes to reinforcing the hydrophobic interactions due to the N-acetamide functions. Simultaneously, the cationicity of the residual amine sites is also increased, thereby reinforcing their hydrophilic nature and their ability to create electrostatic interactions. All these conditions are favorable for the establishment of interactions with the proteoglycans of the extracellular matrix neo-formed by the chondrogenic cells.
- the pH conditions are favorable to the action of enzymes, for example the lysosyme, secreted by the chondrocytes and allowing the degradation by hydrolysis of glycosuric bonds constituting the chitosan chain.
- the chondrocytes multiply and simultaneously synthesize an important matrix which accumulates around the cells and gradually replaces or covers the chitosan hydrogel. It is also possible to follow the formation of this cartilage neo-tissue depending on the culture time.
- the chondrogenic cells adhere to the hydrogel without ever penetrating it, they secrete matrix proteins of the collagen type and proteoglycans which accumulate around the cells and which form a denser layer along the hydrogel. , between the cells and the hydrogel which retains its initial appearance. When the culture continues, especially for four to six weeks, the cells. Chondrogens multiply from the cells lining the hydrogel and matrix proteins continue to accumulate.
- the structure of the hydrogel changes, becoming more loose and gradually taking on colors which are specific for collagen proteins and proteoglycans.
- a block of neoformed tissue is obtained at the end of culture, consisting of several colonies of cells organized in more or less parallel rows and having a cell maturation gradient which is oriented from the junction zone of the cells with the hydrogel towards its periphery. .
- This block of neo-tissue in histology we note that its morphological aspect is close to a normal cartilaginous tissue.
- a molecular analysis by RT-PCR was carried out after five weeks of culture, for the expression of collagens I and II, agrecan, biglycan and decorin.
- the messenger RNAs of collagen II, agrecane, biglycan and decorin are expressed while those of collagen I are not detectable.
- the proteoglycans were extracted from the neo-tissue with guanidine chloride 4M, purified and analyzed by chromatography on a column of sepharose 2B. The elution profiles obtained show that the cells have synthesized and secreted proteoglycans which have gathered in the matrix in the form of high molecular weight aggregates, with a profile similar to those synthesized and secreted in vivo.
- the chondrogenic cells have been spread, in the form of a sheet, between layers of hydrogel, each layer having a thickness of the order of a few millimeters.
- four layers of cells have been spread in combination with three layers of hydrogel, namely two layers respectively on the outer faces of the first and third layers of hydrogel and two layers sandwiched between the first and second layers and the second and third hydrogel layers, respectively.
- the cells were cultured under the same conditions as above and the same observations were made as regards the formation of a cartilage neo-tissue.
- the cell colonies which have formed either from the cells in contact with the outer face of the first and third hydrogel layers or from the cells spread between two layers of hydrogel all exhibit a morphological gradient similar to that which has been described above.
- the hydrogel layers, inserted between the layers of cells, have disappeared and are replaced by a very alkyanophilic fibrillar structure whose thickness corresponds approximately to the superposition of two to three layers of cells. It is understood that this last variant using a superposition of layers of chitosan hydrogel and chondrogenic cells makes it possible very easily to obtain a larger cartilage neo-tissue.
- the cartilaginous neo-tissue which is obtained according to the method of the invention is capable of being grafted as it is for the repair of cartilaginous, meniscal or intervertebral disc lesions, notably lesions of size important.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002442734A CA2442734A1 (fr) | 2001-03-30 | 2002-03-29 | Neo-tissu cartilagineux greffable |
EP02757750A EP1372751A1 (fr) | 2001-03-30 | 2002-03-29 | Neo-tissu cartilagineux greffable |
US10/473,359 US20050074742A1 (en) | 2001-03-30 | 2002-03-29 | Cartilaginous neo-tissue capable of being grafted |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0104405A FR2822842B1 (fr) | 2001-03-30 | 2001-03-30 | Procede de preparation d'un neo-tissu cartilagineux |
FR01/04405 | 2001-03-30 | ||
FR0111322A FR2822843B1 (fr) | 2001-08-31 | 2001-08-31 | Neo-tissu cartilagineux greffable |
FR01/11322 | 2001-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002078761A1 true WO2002078761A1 (fr) | 2002-10-10 |
Family
ID=26212946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/001122 WO2002078761A1 (fr) | 2001-03-30 | 2002-03-29 | Neo-tissu cartilagineux greffable |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050074742A1 (fr) |
EP (1) | EP1372751A1 (fr) |
CA (1) | CA2442734A1 (fr) |
WO (1) | WO2002078761A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI632926B (zh) * | 2009-05-29 | 2018-08-21 | 沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
US10612001B2 (en) | 2014-12-01 | 2020-04-07 | Advanced Chitosan Solutions Biotech | Cartilage gel for cartilage repair, comprising chitosan and chondrocytes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999047186A1 (fr) * | 1998-03-18 | 1999-09-23 | University Of Pittsburgh | Matieres composites a base de chitosane contenant du glycosaminoglycane pour la reparation du cartilage |
WO2000056251A1 (fr) * | 1999-03-24 | 2000-09-28 | Chondros, Inc. | Culture cellulaire et produits de recombinaison polymeres |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6886568B2 (en) * | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
-
2002
- 2002-03-29 US US10/473,359 patent/US20050074742A1/en not_active Abandoned
- 2002-03-29 WO PCT/FR2002/001122 patent/WO2002078761A1/fr not_active Application Discontinuation
- 2002-03-29 EP EP02757750A patent/EP1372751A1/fr not_active Withdrawn
- 2002-03-29 CA CA002442734A patent/CA2442734A1/fr not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999047186A1 (fr) * | 1998-03-18 | 1999-09-23 | University Of Pittsburgh | Matieres composites a base de chitosane contenant du glycosaminoglycane pour la reparation du cartilage |
WO2000056251A1 (fr) * | 1999-03-24 | 2000-09-28 | Chondros, Inc. | Culture cellulaire et produits de recombinaison polymeres |
Non-Patent Citations (3)
Title |
---|
DATABASE MEDLINE [online] October 1998 (1998-10-01), ZHANG W ET AL: "[Tissue engineering of hyaline cartilage]", XP002207812, Database accession no. NLM11825472 * |
FRANCIS SUH J-K ET AL: "Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: a review", BIOMATERIALS, vol. 21, no. 24, 15 December 2000 (2000-12-15), pages 2589 - 2598, XP004217422, ISSN: 0142-9612 * |
ZHONGHUA WAI KE ZA ZHI [CHINESE JOURNAL OF SURGERY], vol. 36, no. 10, October 1998 (1998-10-01), pages 591 - 593, ISSN: 0529-5815 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI632926B (zh) * | 2009-05-29 | 2018-08-21 | 沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
US10612001B2 (en) | 2014-12-01 | 2020-04-07 | Advanced Chitosan Solutions Biotech | Cartilage gel for cartilage repair, comprising chitosan and chondrocytes |
US11718828B2 (en) | 2014-12-01 | 2023-08-08 | Advanced Chitosan Solutions Biotech | Cartilage gel for cartilage repair, comprising chitosan and chondrocytes |
Also Published As
Publication number | Publication date |
---|---|
CA2442734A1 (fr) | 2002-10-10 |
EP1372751A1 (fr) | 2004-01-02 |
US20050074742A1 (en) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3226923B1 (fr) | Gel de cartilage pour la réparation cartilagineuse, comprenant du chitosane et des chondrocytes | |
Kang et al. | Novel porous matrix of hyaluronic acid for the three-dimensional culture of chondrocytes | |
RU2392287C2 (ru) | Матрица, клеточный имплантат и способы их получения и применения | |
US6790454B1 (en) | Processes for the preparation of novel collagen-based supports for tissue engineering, and biomaterials obtained | |
EP3388091B1 (fr) | Réparation de tissu cartilagineux | |
Chung et al. | Interpenetrating polymer network (IPN) scaffolds of sodium hyaluronate and sodium alginate for chondrocyte culture | |
JP2021519060A (ja) | インビトロ培養及び移植のための組織構築物の生理学的3dバイオプリンティングのためのバイオガム及び植物性ガムハイドロゲルバイオインク | |
CA2384768A1 (fr) | Methodes et compositions pour la conservation de chondrocytes et utilisations | |
JP2003534102A (ja) | 組織工学及び生体材料製造のためのコラーゲンベースによる支持体 | |
AU2007229009A1 (en) | Methods to maintain, improve and restore the cartilage phenotype of chondrocytes | |
WO2005044326A1 (fr) | Utilisation d'un hydrogel pour la culture de chondrocytes. | |
US20140341874A1 (en) | Dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair | |
WO2002078760A1 (fr) | Procede de preparation d'un neo-tissu cartilagineux | |
WO2009017267A1 (fr) | Procédé de différenciation de cellules souches mésenchymes et de culture de chondrocytes par le biais de composite fibrine/ha revêtu d'alginate | |
WO2002078761A1 (fr) | Neo-tissu cartilagineux greffable | |
CA2250938A1 (fr) | Laminine 5 pour la croissance des cellules des ilots pancreatiques | |
EP1960011B1 (fr) | Utilisation d' un polysaccharide excrete par l'espece vibrio diabolicus a des fins d'ingenierie des tissus conjonctifs non mineralises | |
FR2809313A1 (fr) | Procedes de preparation de nouveaux supports a base de collagene pour l'ingenieurie tissulaire et biomateriaux obtenus | |
Kumar et al. | Preparation and characterization of biodegradable collagen–Chitosan scaffolds | |
FR2822843A1 (fr) | Neo-tissu cartilagineux greffable | |
FR2927632A1 (fr) | Cornee et muqueuse reconstruites. | |
EP0217816B1 (fr) | Produit a base d'elastine, procede pour sa preparation et ses applications biologiques, en particulier en tant que biomateriaux et supports artificiels | |
Weiss et al. | Hydrogels for cartilage tissue engineering | |
EP2406275B1 (fr) | Peptide promoteur de l'adhesion et de la migration cellulaire | |
WO2020144381A1 (fr) | Procede d'amplification in vitro ou ex vivo de cellules souches du tissu adipeux humain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002757750 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2442734 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002757750 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10473359 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002757750 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |